Table 2.
Median 25(OH)D levels by baseline disease stage and clinical outcomes
| Clinical characteristic | Median 25(OH)D | Interquartile range | P value |
|---|---|---|---|
| KS Clinical Stage | 0.8 | ||
| 2 or 3 | 75 | 57–91 | |
| 4 | 72 | 56–89 | |
| ACTG Stage | 0.4 | ||
| 0 | 73 | 40–85 | |
| 1 | 73 | 58–90 | |
| Survival Status | 0.3 | ||
| Alive at 96 weeks | 69 | 55–85 | |
| Died by 96 weeks | 63 | 46–79 | |
| Clinical Response | 0.7 | ||
| Partial or complete | 64 | 56–88 | |
| No response | 73 | 58–92 | |
| Immune Response | |||
| No KS-IRIS | 73 | 57–89 | 0.7 |
| Developed KS-IRIS | 64 | 56–88 | |
| HIV-1 virological response | 66 | 55–86 | 0.3 |
| HIV-1 virological failure | 83 | 58–93 | |
| Adjunctive therapy | |||
| No chemotherapy | 66 | 52–93 | 0.8 |
| Chemotherapy | 73 | 57–88 | |
| No radiation | 75 | 58–90 | 0.5 |
| Radiation therapy | 67 | 55–86 | |
KS: Kaposi Sarcoma; ACTG: AIDS Clinical Trials Group; KS-IRIS: Kaposi Sarcoma- Immune reconstitution inflammatory syndrome.